[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-335962-en":59,"doc-seo-335962-105":81},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":80,"preview_page_count":4},335962,549758146520,"Patrick","https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Identification of Germline FOXE1 and Somatic MAPK Pathway Gene Alterations in Patients with Malignant Struma Ovarii, Cleft Palate and Thyroid Cancer","Germline variants in the FOXE1 transcription factor have been linked to thyroid ectopy, cleft palate, and thyroid cancer. The study investigates the role of FOXE1 in Portuguese families containing patients with malignant struma ovarii, papillary thyroid cancer, and cleft palate. Two rare heterozygous FOXE1 promoter variants were identified, with functional cell assays showing variant-specific effects on promoter transcriptional activity. Tumor analyses revealed reduced FOXE1 expression, additional germline AXIN1 involvement in one case, and somatic BRAF/HRAS alterations, implicating FOXE1 and MAPK pathway activation in malignant transformation.","Article  \nIdentification of Germline FOXE1 and Somatic MAPK Pathway Gene Alterations in Patients with Malignant Struma Ovarii, Cleft Palate and Thyroid Cancer  \nCarolina Pires 1,2, Ana Saramago 1, Margarida M. Moura 1, Jing Li 3,4,5, Sara Donato 6, Inês J. Marques 1,2, Hélio Belo 1, Ana C. Machado 7, Rafael Cabrera 7, Thomas G. P. Grünewald 3,4,5,8, Valeriano Leite 1,6 and Branca M. Cavaco 1, *  \nCitation: Pires, C.; Saramago, A.; Moura, M.M.; Li, J.; Donato, S.; Marques, I.J.; Belo, H.; Machado, A.C.; Cabrera, R.; Grünewald, T.G.P.; et al. Identification of Germline FOXE1 and Somatic MAPK Pathway Gene Alterations in Patients with Malignant Struma Ovarii, Cleft Palate and Thyroid Cancer. Int. J. Mol. Sci. 2024, 25, 1966. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms25041966](10.3390/ijms25041966)  \nAcademic Editor: Daniela Grimm  \nReceived: 20 December 2023  \nRevised: 25 January 2024  \nAccepted: 1 February 2024  \nPublished: 6 February 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), 1099-023 Lisboa, Portugal; [cs.pires@campus.fct.unl.pt](cs.pires@campus.fct.unl.pt) (C.P.);  \n[aasaramago@ipolisboa.min-saude.pt](aasaramago@ipolisboa.min-saude.pt) (A.S.); [mmoura@ipolisboa.min-saude.pt](mmoura@ipolisboa.min-saude.pt) (M.M.M.);  \n[ines.marques@nms.unl.pt](ines.marques@nms.unl.pt) (I.J.M.); [bc-hbelo@ipolisboa.min-saude.pt](bc-hbelo@ipolisboa.min-saude.pt) (H.B.);  \n[vleite@ipolisboa.min-saude.pt](vleite@ipolisboa.min-saude.pt) (V.L.)  \n2 NOVA Medical School (NMS)-Faculdade de Ciências Médicas, Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal  \n3 Hopp Children’s Cancer Center (KiTZ), 69120 Heidelberg, Germany; [j.li@kitz-heidelberg.de](j.li@kitz-heidelberg.de) (J.L.);  \nt.gruenewald@kitz-heidelberg.de (T.G.P.G.)  \n4 Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany  \n5 National Center for Tumor Diseases (NCT), NCT Heidelberg, a Partnership between DKFZ and Heidelberg University Hospital, 69120 Heidelberg, Germany  \n6 Serviço de Endocrinologia, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), 1099-023 Lisboa, Portugal; [saramldonato@gmail.com](saramldonato@gmail.com)  \n7 Serviço de Anatomia Patológica, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), 1099-023 Lisboa, Portugal; [aicunha@ipolisboa.min-saude.pt](aicunha@ipolisboa.min-saude.pt) (A.C.M.);  \n[racabrera@ipolisboa.min-saude.pt](racabrera@ipolisboa.min-saude.pt) (R.C.)  \n8 Institute of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany  \n* [Correspondence: bcavaco@ipolisboa.min-saude.pt](Correspondence: bcavaco@ipolisboa.min-saude.pt)  \nAbstract: Germline variants in the FOXE1 transcription factor have been associated with thyroid ectopy, cleft palate (CP) and thyroid cancer (TC) . Here, we aimed to clarify the role of FOXE1 in Portuguese families (F1 and F2) with members diagnosed with malignant struma ovarii (MSO), an ovarian teratoma with ectopic malignant thyroid tissue, papillary TC (PTC) and CP. Two rare germline heterozygous variants in the FOXE1 promoter were identified: F1) c.-522G>C, in the proband (MSO) and her mother (asymptomatic); F2) c.9C>T, in the proband (PTC), her sister and her mother (CP) . Functional studies using rat normal thyroid (PCCL3) and human PTC (TPC-1) cells revealed that c.9C>T decreased FOXE1 promoter transcriptional activity in both cell models, while c.-522G>C led to opposing activities in the two models, when co","cbCaim9dCUHseHi6","https://ap.wps.com/l/cbCaim9dCUHseHi6","pdf",4024444,15,"English","en",105,"# Introduction\n## Thyroid cancer background\n## Struma ovarii and malignant transformation\n## Role of FOXE1 in thyroid biology","[{\"question\":\"What was the study’s main goal regarding FOXE1 in these patients?\",\"answer\":\"To clarify the role of FOXE1 in Portuguese families that include members diagnosed with malignant struma ovarii, papillary thyroid cancer, and cleft palate.\"},{\"question\":\"Which FOXE1 promoter variants were identified in the families?\",\"answer\":\"Two rare germline heterozygous variants were reported: c.-522G\\u003eC and c.9C\\u003eT, each segregating in different affected family members and probands.\"},{\"question\":\"How did functional studies and tumor analyses relate to FOXE1 and malignancy?\",\"answer\":\"Functional assays showed that c.9C\\u003eT reduced FOXE1 promoter transcriptional activity, while c.-522G\\u003eC had opposing effects versus wild type. Patient tumor analyses also indicated lower FOXE1 expression versus adjacent normal/hyperplastic tissue, and sequencing uncovered somatic BRAF and HRAS alterations alongside possible AXIN1 involvement.\"}]","Identification of Germline FOXE1 and Somatic MAPK Pathway Gene Alterations in Patients with Malignant Struma Ovarii, Cleft Palate and Thyroid Cancer | PDF",1790012970,38,{"code":4,"msg":82,"data":83},"ok",{"site_id":75,"language":74,"slug":84,"title":65,"keywords":85,"description":66,"schema_data":86,"social_meta":140,"head_meta":142,"extra_data":144,"updated_unix":145},"identification-of-germline-foxe1-and-somatic-mapk-pathway-gene-alterations-in-patients-with-malignant-struma-ovarii-cleft-palate-and-thyroid-cancer","",{"@graph":87,"@context":139},[88,102,122],{"@type":89,"itemListElement":90},"BreadcrumbList",[91,95,97,100],{"item":92,"name":93,"@type":94,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":96,"name":9,"@type":94,"position":14},"https://docshare.wps.com/document/",{"item":98,"name":40,"@type":94,"position":99},"https://docshare.wps.com/document/research-report/",3,{"item":101,"name":65,"@type":94,"position":19},"https://docshare.wps.com/document/identification-of-germline-foxe1-and-somatic-mapk-pathway-gene-alterations-in-patients-with-malignant-struma-ovarii-cleft-palate-and-thyroid-cancer/335962/",{"url":101,"name":65,"@type":103,"image":104,"author":109,"headline":65,"publisher":111,"fileFormat":114,"inLanguage":74,"description":66,"dateModified":115,"datePublished":116,"encodingFormat":114,"isAccessibleForFree":117,"interactionStatistic":118},"DigitalDocument",{"url":105,"@type":106,"width":107,"height":108},"https://docshare.wps.com/thumbnails/identification-of-germline-foxe1-and-somatic-mapk-pathway-gene-alterations-in-patients-with-malignant-struma-ovarii-cleft-palate-and-thyroid-cancer/335962.png","ImageObject",300,407,{"name":63,"@type":110},"Person",{"url":92,"name":112,"@type":113},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":119,"interactionType":120,"userInteractionCount":52},"InteractionCounter",{"@type":121},"ViewAction",{"@type":123,"mainEntity":124},"FAQPage",[125,131,135],{"name":126,"@type":127,"acceptedAnswer":128},"What was the study’s main goal regarding FOXE1 in these patients?","Question",{"text":129,"@type":130},"To clarify the role of FOXE1 in Portuguese families that include members diagnosed with malignant struma ovarii, papillary thyroid cancer, and cleft palate.","Answer",{"name":132,"@type":127,"acceptedAnswer":133},"Which FOXE1 promoter variants were identified in the families?",{"text":134,"@type":130},"Two rare germline heterozygous variants were reported: c.-522G>C and c.9C>T, each segregating in different affected family members and probands.",{"name":136,"@type":127,"acceptedAnswer":137},"How did functional studies and tumor analyses relate to FOXE1 and malignancy?",{"text":138,"@type":130},"Functional assays showed that c.9C>T reduced FOXE1 promoter transcriptional activity, while c.-522G>C had opposing effects versus wild type. Patient tumor analyses also indicated lower FOXE1 expression versus adjacent normal/hyperplastic tissue, and sequencing uncovered somatic BRAF and HRAS alterations alongside possible AXIN1 involvement.","https://schema.org",{"og:url":101,"og:type":141,"og:title":65,"og:site_name":112,"og:description":66},"article",{"robots":143,"canonical":101},"index,follow",{"doc_id":61,"site_id":75},1790351957]